Depomed, Inc. (NASDAQ: DEPO) today announced that it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, and NUCYNTA® (tapentadol), an immediate release version of tapentadol. The deal will make NUCYNTA the flagship asset in Depomed’s growing portfolio of pain and neurology specialty pharmaceuticals.
Baker Botts represented Depomed in the acquisition.
Baker Botts Lawyers/Office Involved: John Martin (Partner, Palo Alto); Brian Lee (Partner, Palo Alto); Scott Mollett (Associate, Palo Alto); Clark Wilkes (Associate, Palo Alto); Don Lonczak (Partner, Washington); Paul Ragusa (Partner, New York); Jon Platt (Associate, Dallas); Luke Weedon (Partner, Dallas); Mark Johnson (Associate, Dallas).
Source: www.bakerbotts.com
